IL17A and glioblastoma: Experimental and biomedical studies on T lymphocytes have shown that NaVPA–NaDCA inhibits inflammatory and immune pathways necessary for the growth of GBM; gene sequence analysis revealed a significant effect of NaVPA–NaDCA on inhibiting inflammatory mechanisms, leading to the downregulation of inflammation-related genes involved in the cytokine activity pathway, the inflammatory response pathway, and the IL-17 signaling pathway in mouse thymocytes [42].